Arbutus Biopharma Corporation (ABUS)

Several events have impacted ABUS's stock price in the past six months. Arbutus Biopharma reported its Q3 2025 earnings, with an EPS of -$0.04, beating estimates, though revenue was below expectations, and shares rose due to promising data from its imdusiran therapeutic. Chardan Capital maintained a "Buy" recommendation for ABUS. A patent dispute with Moderna escalated, and the stock declined after the European Patent Office revoked one of Arbutus's patents. Market sentiment shifted, and shares jumped after a judge ruled that the patent dispute with Moderna must proceed to a jury trial. As of February 2, 2026, the share price was $4.39, representing a 33.84% increase from February 3, 2025.

As a clinical-stage biopharmaceutical company, Arbutus Biopharma's products are in the development phase, so there is no typical demand seasonality for its products and services. Demand for its future products will be driven by clinical trial outcomes and eventual regulatory approvals, rather than seasonal patterns.

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing a cure for chronic hepatitis B virus (HBV) infection and has initiated drug discovery and development efforts for coronaviruses, including COVID-19. The company operates within the Healthcare sector and Biotechnology industry. Its main product candidates in clinical trials include Imdusiran (AB-729), an RNAi therapeutic designed to suppress all HBV antigens, and AB-101, an oral PD-L1 inhibitor aiming to reawaken patients' HBV-specific immune response. The company also possesses a Lipid Nanoparticle (LNP) delivery technology, which is central to ongoing intellectual property litigation.

Arbutus Biopharma Corp. is headquartered in Warminster, Pennsylvania, United States, and focuses on developing novel therapeutics for infectious diseases within the United States.

Arbutus Biopharma's reputation has been influenced by its clinical progress and legal battles. The company's reports have an aggregate usefulness score of 4.8 out of 5.0 based on 206 reviews. Analyst ratings show a mixed view, with one Wall Street analyst giving a "Strong Buy" consensus rating, while another source indicates a "Hold" consensus based on two research reports. Positive events impacting its reputation include strategic partnerships and a robust research and development program. Conversely, the ongoing intellectual property litigation with major pharmaceutical companies poses a significant risk. The retirement of Mike Sofia, Co-Founder and Chief Scientific Officer, was also a notable event. Risks to its reputation and future include intense competition in recruiting patients for clinical programs and the potential for therapies to fail to meet clinical efficacy endpoints.

Arbutus Biopharma Corporation has 273 institutional owners and shareholders who collectively hold 135,530,508 shares. Major institutional shareholders include Morgan Stanley, Whitefort Capital Management, LP, BlackRock, Inc., Two Seas Capital LP, Vanguard Group Inc, Adage Capital Partners Gp, L.l.c., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, CPOAX - Morgan Stanley Insight Fund A, State Street Corp, and iShares Russell 2000 ETF. Institutions hold 43.79% of the company's stock, while insiders hold 20.30%.